Fulgent Genetics announced the acquisition of selected assets of Bako Diagnostics and StrataDx for approximately $55.5 million.
The acquisition will expand Fulgent's laboratory services business and national client base.
Fulgent aims to enhance its test menu and accessibility through strategic acquisitions.
Artificial Intelligence for Pathology
Investments in AI and digital pathology to enhance capacity and efficiency.
Test Menu Expansion
Acquisition includes Bako's proprietary PCR tests for optimized cost and rapid results.
Commercial Synergies
Bako and StrataDx's capabilities will advance Fulgent's goal of being a one-stop-shop for diagnostic services.
Geographic Reach
Expansion into Georgia and Massachusetts with certified laboratories.
- The acquisition strengthens Fulgent's presence in the pathology testing market.
- Bako and StrataDx bring advanced technology and expertise to complement Fulgent's services.
Fulgent Genetics continues to grow its laboratory services platform and aims to leverage the new acquisitions to enhance efficiency and quality in diagnostic services.